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Introduction: Vagus nerve stimulation (VNS) is an effective alternative treatment for
patients with partial refractory epilepsy. Nevertheless, information regarding VNS in
children is still limited.
Materials and methods: The clinical efficacy, safety and neuropsychological effects
of VNS in 34 children (mean age 11.5 years) with drug-resistant epilepsy were studied.
Mean follow-up was 30.8 months.
Nine patients have been diagnosed with Lennox—Gastaut Syndrome, nine patients
were affected by severe partial epilepsy with bisynchronous EEG and drop attacks,
and 16 patients suffered from partial epilepsy without bisynchronous EEG and fall
seizures. Forms were designed for prospective data collection on each patient’s
history, seizures, implants, device settings, quality of life (QOL), neuropsychological
assessment and adverse events. Surgical technique was performed both by standard
two incisions and single neck incision.
Results: Mean reduction in total seizures was 39% at 3 months, 38% at 6 months, 49%
at 12 months, 61% at 24 months and 71% at 36 months. Significant better results were
obtained in partial epilepsy, with and without drop attacks, than in Lennox—Gastaut
syndrome–—three patients being seizure-free. No operative morbidity was reported.
Side-effects were minor and transient–—the most common were voice alteration and
coughing during stimulation. In two patients, electrode breakage occurred 3 years
after surgical procedure; in both cases, a new device was implanted after removing
the vagal electrode coils and generator.* Corresponding author. Tel.: +39 071 596 4551; fax: +39 071 596 4575.
E-mail address: f.ryc@ao-umbertoprimo.marche.it (F. Rychlicki).
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Conclusion: VNS can be considered an appropriate strategy as an add-on treatment in
children affected by drug-resistant partial epilepsy and ineligible for resective
epilepsy surgery.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Vagus nerve stimulation (VNS) can be considered a
non-pharmacological therapy for patients with
intractable epilepsy who are ineligible for resective
epilepsy surgery.1
Over the last decade, the advent of VNS has
aroused renewed interest in neurostimulation and
opened up new perspectives in the treatment of
epilepsies.2 It is evident that VNS offers substantial
therapeutic benefit to some patients without causing
major side-effects. In most situations, VNS is consid-
ered a palliative treatment with the goal of reducing
the frequency and severity of seizures, although a
small proportion (about 5%) of patients with VNS
implants have been reported as seizure-free.2,3—5
In adults, the technique has been used on a wide
scale, but little data are available on the use of VNS
therapy in children with refractory epilepsy. Results
from small observational studies suggest that the
therapeutic effect of VNS is better in children than
in adults, and the benefit in children is achieved
more rapidly.1,3,6,7—17
In a recent study on 60 children (mean age: 15
years), the median reduction in seizure frequency
was 44%.10
A retrospective study in six epilepsy centers eval-
uating the effectiveness of VNS therapy in 125
children with Lennox—Gastaut Syndrome (LGS),
reported an average seizure reduction of 36.1% at
3 months and 44.7% at 6 months.18
This clinical, non-randomized, prospective study
of a series of pediatric patients reports our clinical
experience in evaluate the effectiveness and safety
of VNS, especially in the most severe and advanced
cases, such as LGS, and to identify any variations
that may exist in responses among different epilep-
tic syndromes.
We also provide preliminary data on the effects of
different stimulation conditions (standard versus
intermediate cycle).Material and methods
Patients
Thirty-four patients (21 male and 13 female) with
drug-resistant epilepsy were included.Patients were eligible for the study if they met
the following criteria:(1) Lennox—Gastaut Syndrome;
(2) partial epilepsy with multiple seizure types,
bisynchronous EEG and drop attacks;
(3) partial epilepsy with multiple seizures, without
bisynchronous EEG and drop attacks;
(4) absence of progressive or systemic diseases;
(5) seizure frequency higher than 10 permonth with
interictal period shorter than 3 weeks, despite
maximal drug treatment regimens;(6) epilepsy history lasting more than 3 years or
catastrophic epilepsy of infancy.Patients with severe swallowing difficulties,
severe self-mutilating behaviour, recent onset
epilepsy, progressive metabolic or degenerative
disease, congenital heart defects, gastrointe-
stinal diseases (mainly gastroesophageal reflux),
or with poor parental collaboration, were not
included.
Patient’s age ranged from 1.4 to 18 years (mean
age: 11.5 years).
Nine patients suffered from Lennox—Gastaut Syn-
drome, nine patients suffered from partial epilepsy
with drop attacks and secondary bisynchronism on
the EEG and 16 patients had partial epilepsy without
drop attacks.
Etiology of epilepsy was cryptogenic in 14
patients and symptomatic in 20.
The etiology of symptomatic forms includes five
patients with neurological damage secondary to
prematurity and perinatal anoxic/ischemic lesions,
three patients with herpethic encephalitis, four
patients with neurological sequels of bacterial
meningoencephalitis, three patients with cortical
dysplasia, two patient with Bourneville tuberous
sclerosis, one patient with vascular malformation
of the middle cerebral artery, one patient with
neurological sequels of near SIDS and one patient
with chromosomopathy.
All but three patients had multiple seizures–—in
18 cases, tonic or atonic drop attacks were present.
Overall, mean seizure frequency was always very
high. Twenty-seven patients had daily seizures up to
a maximum of 40 seizures per day. Seven patients
had 8—20 seizures per month (average seizure fre-
quency per month: 297.5).
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epileptic drugs, in variable associations, had been
tried unsuccessfully.
Interictal and ictal EEGs were available in all
patients. The seizure characteristics were assessed
by video-EEG recordings in 27 patients.
Neuropsychological assessment showed severe
mental retardation in 22 cases, moderate in seven
cases and mild mental retardation in four. One
patient had a normal intelligence quotient (IQ).
Focal neurologic disorders, including hemiparesis
or tetraparesis, were present in 22 cases.
School attendance, with the support of a
personal teacher, was possible in all school-age
children.
Lennox—Gastaut Syndrome
Nine patients (8 male/1 female) have been diag-
nosed with Lennox—Gastaut Syndrome.
They showed the typical electroclinical pattern
of the syndrome and in eight patients spasms were
present in the first 5 months of life.
Mean age at implant operation was 11.1 years,
with a mean epilepsy duration of 9.6 years.
Multiple seizures (atypical absences, tonic sei-
zures, tonic—clonic generalized seizures) were pre-
sent, with frequent and very disabling tonic or
atonic drop attacks (average seizure number:
330.6 per month)
All patients showed neurological focal deficits
and mental retardation–—severe in seven cases
and moderate in two cases.
Partial severe epilepsy with drop attacks and
bisynchronous EEG (Pseudo-Lennox Syndrome)
Nine patients (4 male/5 female) were affected by
partial epilepsy with multifocal frontal or fronto-
temporal EEG abnormalities and important second-
ary bilateral synchrony. Multiple seizures were
present, mainly partial complex or secondary gen-
eralized and drop attacks. Usually, falls followed a
tonic asymmetric contraction of axial and leg mus-
cles leading to a loss of balance.
Mean age at implantation was 8.53 years, with a
mean epilepsy duration of 7.8 years and an average
seizures number per month of 457.8.
Severe (n = 8) or moderate (n = 1) mental handi-
caps were present in all patients.
Partial epilepsy without drop attacks
Sixteen children (9 male/7 female) had partial epi-
lepsy with polymorphic seizures, mainly complex
partial or secondary generalized without tonic
seizures and drop attacks.
The EEG pattern was characterized by focal or
multifocal discharges without secondary diffusion.Mean age at surgery was 13.5 years, with a mean
epilepsy duration of 9.2 years and an average num-
ber of seizures per month of 188.8.
Severe mental retardation was present in
seven patients–—four children showed moderate
mental retardation, four mild and one had a nor-
mal IQ.
Study design
Forms were designed for prospective data collection
on each patient’s history, seizures, drug therapy,
implant, device settings and side-effects.
Patients were assessed prior to implantation and
3, 6, 12, 24 and 36 months after surgery. The mean
follow-up time was 30.8 months (range: 3—51.8
months).
Medical outcome measures
Once the definitive target parameters of stimulation
were reached, the follow-up was extended to every
3 months in the first year and to every 6 months in
subsequent years to evaluate the degree of toler-
ance and clinical efficacy of VNS.
Clinical efficacy was determined by comparing
the seizure frequency during the last 3 months of
follow-up with the seizure frequency during the pre-
implantation period, using the following equation:
[seizures/month on VNS—baseline seizures/
month]/[baseline seizures/month]  100.3
Seizures were encoded, according to the Inter-
national League against Epilepsy classification, as
follows: complex partial seizures (CPS), complex
partial secondary generalized (CPSG), myoclonic
seizures, tonic seizures, tonic—clonic seizures,
absence, drop attacks.12
Complex partial seizures and the drop attacks
were scored separately.
The antiepileptic therapy was not changed during
the first 6 months after surgery, with exception of
three patients who presented a status epilepticus.
2.2.2. Neuropsychological outcome measures
QOL was assessed by using the Vineland adaptive
behavior scale (VBAS). VBAS is a well-standardized
measure of functional behavior and can be used on
all children with epilepsy and learning disabilities.
VBAS evaluates the social and personal grade of
autonomy of an individual. Because it is adminis-
tered by interview of parents or carers, it does not
require the presence or collaboration of the patient
and also provides a global functional assessment
in subjects with severe neuropsychological disor-
ders. It is divided into five general areas, including
communication, socialization, daily living skills,
movement abilities and disturbed behaviours.19
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Fig. 1 Summary of seizure-frequency reduction rate in
all patients.
Fig. 2 Percentage of patients with >50% seizure reduc-
tion over the follow-up period.The test was administered to the 21 treated
patients before VNS (baseline) and after 18months,
and to a homogenous control group of 21 epileptic
subjects.
Mental age was assessed using a battery test
consisting of three different cognitive tests: WISC-
RN or Stanford—Binet (Terman—Merrill) scales or
Brunet—Lezine scale, depending on the level of
mental functioning
Statistical analysis
Seizure frequency changes in the pre- and post-
implant period were verified by the t-test for paired
samples. Comparison between two or more groups
was performed by an unpaired t-test and one-way
factorial ANOVA.
The correlation between some clinical para-
meters, such as epilepsy duration, chronological
age at implant, seizure number pre-VNS, mental
retardation, etiology, epileptic syndrome and VNS
response were evaluated by Fisher’s exact test from
2  2 contingency tables.
P-values < 0.05 were considered to be statisti-
cally significant.
Surgical procedure
Implantation technique has been described else-
where.14
The first 10 patients in our series underwent a
standard VNS procedure with neck and chest inci-
sions.
Since 2001, the surgical technique has been mod-
ified by using a single cervical incision. The upper
retraction of the wound allows exposure of the vagal
nerve, while the lower retraction is used to create a
subclavicular pocket to host the stimulating unit at a
distance of about 7 cm from the electrodes. The
pulse generator is placed underneath the pectoralis
major muscle and secured to the fascia of the
intercostal musculature.
Stimulation parameters
Children were discharged 72 h after surgery. On
post-operative day 3, the neurostimulator was
switched on and, thereafter, the children were
re-evaluated as outpatients every week for 1 month
for the ramp-up.
The intensity of stimulation, beginning 0.50 mA,
was increased, in steps of 0.50 mA, until the stimu-
lation parameters reached 2 mA at a frequency of
30 c/s, with an OFF-period of 5 min alternating with
an ON-period of 30 s (standard stimulation setting).
During this adjustment period, ECG-coupled poly-
graphic EEG was systematically performed at the
beginning of activation and while the intensity of
stimulation reached 1 and 2 mA. In 17 cases, thestandard stimulation setting was switched to an
intermediate stimulation pattern (ON period 30 s




Data are available for 33 patients at 3 months of
treatment. In this period, VNS produced a mean
seizure rate reduction of 39% (P = 0.004)
At 12 months, data are available for 29 patients.
The seizure reduction rate was 49% (P = 0.003).
Twenty-four patients had a 2-year follow up, with
a mean seizure reduction rate in this group of 61%
(P = 0.008). Seizure reduction rate in the 15 patients
with a 3-year follow-up was 71% (P = 0.002) (Fig. 1).
At 3 months follow-up, 48% of treated patients
were considered responders. The percentage
increased to 55 and 71% at 1 and 2 years, respec-
tively (Fig. 2).
Ten of 29 patients with a 12-month follow-up had
a reduction in seizure frequency exceeding 70%.
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Fig. 3 Seizure-frequency reduction rate in Lennox—Gas-
taut Syndrome.
Fig. 5 Seizure-frequency reduction rate in partial epi-
lepsy.In 19 patients (55.8%), the clinical response was
achieved early after surgery with stimulation inten-
sities between 0.75 and 1.25 mA.
Three patients showed a transient worsening of
seizure pattern during the first 3 months of treat-
ment.
In eight patients, clusters of seizures, alternating
with prolonged seizure-free periods during the first
6 months of treatment, were also observed.
At present, three patients (8.8%) reported a sei-
zure-free period lasting more than 1 year. All of
them were affected from partial epilepsy without
drop attacks.
Lennox—Gastaut Syndrome
Among patients with Lennox—Gastaut Syndrome,
the mean reduction in seizure frequency was 8%
at 3 months (n.s.) 33% at 12 months (n.s) and 50%
at 2 years (n.s.) (Fig. 3).
Severe partial epilepsy
The average reduction in seizure frequency among
patients with severe partial epilepsy with drop
attacks was 58% (P = 0.02) and 65% at 3 and 12
months, respectively (P = 0.02). Only eight patients
had more than 2 years follow-up–—the mean seizureFig. 4 Seizure-frequency reduction rate in Pseudo-Len-
nox—Gastaut Syndrome.reduction rate in these children was 59% (P = 0.02)
(Fig. 4).
Partial epilepsy
Patients with partial epilepsy had a mean reduction
in seizure frequency of 46% at 3 months (P = 0.09)
and 50% at 12 months (P = 0.02). At 2 years follow-
up, mean reduction was 69% (P = 0.01) (Fig. 5).
Clinical effectiveness differed significantly
among the three considered groups (P = 0.001).
Factors strongly correlated with a better clinical
response were: age at implantation less than 12 years (P = 0.009);
 epileptic syndromes, such as partial epilepsy ver-
sus the others (P = 0.01); epilepsy duration less than 6 years (P = 0.05).
Other suggested variables, i.e. etiology, number
of seizures and mental retardation, have not been
shown statistical significance.
Drop attacks and other seizure types
Data were further analyzed by seizure type.
Drop attacks, present in 18 patients, decreased
by 38% at 1 year and 53% at 2 years. Partial seizures,
present in 25 patients, decreased by 58 and 67% at 1
and 2 years respectively. No significant difference in
clinical response exists between the two seizure
types.
Device setting
All the patients were initially set on standard sti-
mulation conditions (2 mA, 30 c/s, OFF time 5 min,
ON time 30 s) Vagus nerve stimulation parameters
were switched to intermediate cycle (OFF time
3 min, ON time 30 s) in 17 of 34 patients owing to
low efficacy of the previous treatment. After amean
period of 8 months, six patients (35.2%) reported a
further mean seizure reduction of 21% without side-
effects.
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Patients consumed an average of 2.9 antiepileptic
drugs (AEDs) before operation. At the cut-off date,
the mean number of AEDs was reduced to 1.8.
At 2 years follow-up, 8 of 24 patients were able to
simplify their drug therapy. In five children, the AED
number was reduced, while in three there was a
dosing reduction without compromising seizure con-
trol.
Nine patients received psychotropic medications
for concomitant autistic spectrum disorders. At 2
years follow-up, the therapy was discontinued in
five children.
Twelve patients received levetiracetam in add-on
therapy. Only four patients showed a further seizure
reduction of 26%. The occurrence of psychotic beha-
vior required the discontinuation of the drug in two
patients.
Neuropsychological outcome
Data are available for 21 patients followed for more
than 18months and for 21 control subjects. No clear
cognitive improvement, but also no major disrup-
tion, was evident on the clinical sample. On
the VABS scores, there was a positive trend,
especially in the motricity (P = 0.04) and the
sociability domains (P = 0.05). For three patients,
the improvement was significant. The control group
showed a significant decrease in the adaptive beha-
vior score (P < 0.01), particularly in the commu-
nication and daily living skills domains. In the
treated group, parental satisfaction and subjective
QOL, evaluated by analogical scale, showed a sig-
nificant improvement–—seemingly related to sei-
zure and AEDs reduction and the entity of mental
retardation pre-VNS.
Side-effects
The surgical procedure was well tolerated in all
cases without noticeable complications.
The aesthetic damage, related to the size of the
stimulator, was acceptable in all the cases. Hyper-
trophic chest scars developed in six of our first 10
patients. The recent implantation modification pro-
cedure, using a single cervical incision, reduced this
discomfort, particularly in small children with small
muscular mass.
In four cases, transient pain was reported at the
neurostimulator implantation site.
Fifteen patients reported hoarseness and
coughing during the setting phase, i.e. when
increasing the stimulation parameters. Both these
events resolved in 1—2 days after stimulation
adjustments.A change in the vocal timbre was reported
in all patients during the stimulation period;
however, this never represented a significant
problem.
In two patients, electrode breakage occurred 3
years after surgical implantation. In both cases,
device malfunction was suspected for the high
values of impedance occasionally found during a
lead check and was subsequently confirmed by X-
ray examination. It is noticeable that we did not
observe worsening of seizures at that time. Drop
attacks or trauma were not reported in the two
children who received the first lead model of the
neurocybernetic prosthesis. A new device was
implanted after removing the vagal electrode coils
and the generator.Discussion
The global outcome of VNS treatment in our pedia-
tric patient series confirms earlier reports.7,9,10,18,20
Moreover, our data showed that seizure-free
patients, or those who experienced a >75% seizure
reduction, are a more consistent group. Literature
data show that seizure-free patients are 2—3% of all
treated patients and those with a >75% seizure
reduction are about 20%.4,5
The aim of this prospective study was to evaluate
the effectiveness and safety of VNS therapy in
children and to identify the type of epileptic syn-
drome related to the best results.
At present, literature data does not characterize
which type of epilepsy is most suitable for surgical
treatment by VNS.
Pediatric series are often heterogeneous and
include several different types of epileptic syn-
dromes. Owing to the limited number of cases in
each study, no stratification can be performed to
achieve amore homogeneous group. In addition, the
duration of the follow-up periods and changes in
drug regimens are frequently not specified.8—12,16,18
Our series includes two types of epileptic
syndrome, i.e. Lennox—Gastaut Syndrome and par-
tial epilepsy. In this last group, we analyzed a
subgroup of children with a peculiar electroclinical
pattern characterized by multifocal, mainly fron-
tal, EEG abnormalities and important bilateral syn-
chrony associated with polymorphic seizures,
mainly tonic and drop attacks. These patients
developed a progressive mental deterioration so
that they look like children with Lennox—Gastaut
Syndrome.
Seizures become more and more frequent and
disabling so that callosotomy is sometimes consid-
ered the correct surgical therapy.21
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patients, in which drop attacks are the most impor-
tant type of seizures, VNS can provide a significant
improvement in seizure control. In spite of the small
number of patients in the study, the clinical effec-
tiveness of the VNS seems greater in the group of
patients with partial epilepsy and drop attacks than
in the group of patients with Lennox—Gastaut
Syndrome.
This result is similar to that reported in two
neurosurgical studies where callosotomized
patients with an EEG pattern of secondary bilateral
synchrony, drop attacks and partial seizures had a
better outcome than patients with generalized epi-
lepsies.13,21
At present, VNS is considered the first surgical
option for treatment of Lennox—Gastaut and
related syndromes and takes precedence over cal-
losotomy because it is less invasive, reversible and
with few serious side-effects.13
As regards patients with Lennox—Gastaut Syn-
drome, some studies indicate that VNS can produce
satisfactory seizure control while others studies
have failed to demonstrate significant efficacy.7,8,11
Our results are consistent with the latter considera-
tion.
The results in patients with partial epilepsy, with-
out drop attacks and independent EEG abnormal-
ities, confirm previous studies.3,22
In these patients, where multiple seizures are not
associated with encephalopathy, the treatment
with VNS allows prolonged seizure-free periods,
suggesting a positive correlation between efficacy
and preserved mental function level.12
In our series, the positive response was achieved
very early after surgery and progressively improved
with time, confirming that the duration of stimula-
tion is the most important factor in clinical long-
term improvement, due to the cumulative effect of
continuous electrical stimulation on the vagus
nerve.20,23
Initial seizure reduction can be obtained with an
amplitude of stimulation, which is usually consid-
ered ‘non-therapeutic’. This observation supports
the hypothesis that, at least for pediatric patients,
intensities of stimulation lower than those com-
monly used in clinical practice for adults can be
therapeutic.
The role of the stimulation parameters is still
controversial. Currently, it is established that ampli-
tude not higher than 2 mA and a standard cycle (OFF
5 min, ON 3 min) is more effective than a duty cycle
(OFF 20 s, ON 7 s).
The role of the intermediate cycle (OFF 3 min,
ON 30 s) is still not clear.13,17,18,22 Our cases and
other sporadic reports in the literature suggest thatsome patients may benefit from a reduction in OFF
time of 1—3 min.13,23
It has been recently suggested that the associa-
tion with some AEDs, mainly levetiracetam, could
have a synergic effect with VNS.24
This data was not confirmed in our experience.
The side-effects of short- and long-term VNS
are mild. Common adverse effects, such as cough,
hoarseness, voice alteration, tend to improve and
disappear with time. Lead breakage must be con-
sidered an important complication rarely reported
in the literature.25 In this case, it became manda-
tory to perform a new surgical procedure after
removing all previous devices, but sometimes it is
not possible to remove the coils without damaging
the vagus nerve, while it is not so easy to find a free
nerve tract to host the coils.Conclusions
Vagus nerve stimulation is an effective palliative
treatment for patients with refractory epilepsy.
In the present study, about 55% of patients
showed a considerable improvement in seizure con-
trol, with a reduction in seizure frequency of at least
50%.
Clinical response was evident early and efficacy
progressively improved with the duration of treat-
ment up to 24 months post-operatively.
The best responders can be considered children
with highest mental age affected with partial epi-
lepsy with and without drop attacks.
A small number of patients with partial epilepsy
experienced long-term complete freedom from sei-
zures and, during this time, the patients may func-
tion at a higher level in daily activities and obtain
considerable improvement in QOL and neuropsycho-
logical performances.
Clinical effectiveness seems higher in younger
children with a short epilepsy history, suggesting a
precocious useful role for VNS.26
Long-term clinical studies, with larger homoge-
neous series of patients, are needed to further
define the best responders and to direct the search
for optimal stimulation parameters and operation
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